Aragen launches ChemiSHE, India’s first women-led chemistry synthesis lab

CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years

CDSCO reforms cut trial approval timelines by over 50%: DCGI Dr Rajeev Raghuvanshi

Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews

Experts seek insurance coverage for stroke rehabilitation as recovery costs rise

Experts also underscored the growing role of technologies such as tele-neurorehabilitation, robotics, and AI-driven therapies in improving recovery outcomes

FDA greenlights Biocon’s Liraglutide for chronic weight management

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management

Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

Aragen slashes drug development time with CHOMax platform

CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes

Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials

The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates

Biocon launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands

Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation

Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly

Aragen appoints Neeraj Garg as CEO - Discovery Solutions business

In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base